Peter Morkos

Microbiome-Based Therapeutics in Oncology: Expanding Indications Beyond C. difficile

The intestinal microbiome has emerged as a clinically significant modulator of outcomes across multiple domains of cancer care. In hematopoietic stem cell transplantation (HSCT), loss of microbial diversity and depletion of short-chain fatty acid-producing commensals are independ...